Ryvu Therapeutics S.A. (WSE:RVU)

Market Cap	601.12M
Revenue (ttm)	101.96M
Net Income (ttm)	-111.44M
Shares Out	23.12M
EPS (ttm)	-4.82
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	121,776
Average Volume	124,420
Open	27.10
Previous Close	27.10
Day's Range	25.70 - 28.00
52-Week Range	17.62 - 56.90
Beta	0.63
RSI	58.01
Earnings Date	Mar 14, 2025

About Ryvu Therapeutics

Ryvu Therapeutics S.A., a biotechnology company, engages in developing of small molecule therapies for treatment in oncology in Poland, rest of the European Union, and internationally. Its lead candidate, RVU120, is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat hematological malignancies, solid tumors, acute myeloid leukemia, myelodysplastic syndrome, and myelofibrosis. The company also develops SEL24/MEN1703, a dual PIM and FLT3 kinase inhibitor licensed to the Menarini Group that is in study start-up for ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 328
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: RVU

Financial Performance

In 2024, Ryvu Therapeutics's revenue was 101.96 million, an increase of 51.51% compared to the previous year's 67.30 million. Losses were -111.44 million, 21.0% more than in 2023.